公开(公告)号：EP4491745A1

公开(公告)日：2025-01-15

申请号：EP23767176.3

申请日：2023-03-08

Applicant: Korea Advanced Institute of Science and Technology

Inventor： CHO, Kwang Hyun ,  GONG, Jeong Ryeol ,  KIM, Ju Hee

IPC: C12Q1/6886 ,  C12N9/10

Abstract: The present invention relates to a composition comprising a SETMAR inhibitor for preventing or treating cancer. It has been identified that if SETMAR is inhibited in cancer cells, carcinogenesis reversion, which is the differentiation of cancer cells into normal cells, is successfully achieved, and thus, unlike conventional anticancer agents that simply induce cancer cell death, the present invention can be effectively used as a treatment method excluding the side effect of normal cell death that can occur during anticancer treatment, and converting cancer cells into normal cells.

公开(公告)号：EP4455664A1

公开(公告)日：2024-10-30

申请号：EP22912037.3

申请日：2022-12-23

Applicant: Korea Advanced Institute of Science and Technology

Inventor： CHO, Kwang Hyun ,  LEE, Hye Min ,  GONG, Jeong Ryeol

IPC: G01N33/50 ,  A61P35/00

Abstract: The present invention relates to a composition comprising a TAF10 inhibitor for preventing or treating colorectal cancer. The inhibition of TAF10 was found to lead to suppressing the growth and proliferation of colorectal cancer cells, reducing vascularization, and inhibiting the WNT signaling pathway, and increase the survival rate of patients as analyzed with a large-scale cancer database. In particular, reversal of the cancerization process, which is the differentiation of colorectal cancer cells into normal cells, was confirmed. Unlike conventional anticancer agents that simply induce the death of cancer cells, the present invention can thus be advantageously utilized as a treatment method for converting colorectal cancer cells into normal cells while excluding side effects of normal cell death that may occur during anticancer treatment.

公开(公告)号：EP4498085A1

公开(公告)日：2025-01-29

申请号：EP23775311.6

申请日：2023-03-22

Applicant: Korea Advanced Institute of Science and Technology

Inventor： CHO, Kwang Hyun ,  LEE, Jung Eun ,  GONG, Jeong Ryeol

IPC: G01N33/50

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer, comprising a DEAD-box helicase 54 (DDX54) inhibitor and a cancer immunotherapy agent, and to a combination therapy of cancer immunotherapy. The DDX54 inhibitor according to the present invention can enhance the efficacy of cancer immunotherapy when used in combination with a cancer immunotherapy agent, and the composition containing the DDX54 inhibitor and a cancer immunotherapy agent inhibits proliferation of cancer, which is a key characteristic thereof, and simultaneously inhibits a signal transduction pathway known as an immune evasion mechanism, and thus may be provided for the prevention or treatment of cancer.

公开(公告)号：EP4497836A1

公开(公告)日：2025-01-29

申请号：EP23775342.1

申请日：2023-03-23

Applicant: Korea Advanced Institute of Science and Technology

Inventor： CHO, Kwang Hyun ,  GONG, Jeong Ryeol ,  LEE, Chun Kyung ,  KIM, Hoon Min ,  KIM, Ju Hee

IPC: C12Q1/6886 ,  C12N5/09 ,  C12N15/85 ,  A61P35/00

Abstract: The present invention relates to a method for constructing a gene network through a single-cell transcriptome and a method for discovering key genes in differentiation using same, and a composition for the prevention, alleviation, or treatment of colon cancer using the target discovered through the method. The method for constructing a gene network of key genes according to the present invention employs single-cell transcriptome data and thus can be applied to all single-cell transcriptome data. The combination of MYB/HDAC2/FOXA2 discovered upon application to colon cells can serve as a cancer treatment target that promotes the differentiation of colon cancer cells to revert same into differentiated normal cells.